Why isn't Pfizer's COVID-19 vaccine OK'd yet? White House calls in FDA chief Hahn to explain: Axios Bipartisan COVID-19 package includes $100B for providers, short-term liability protections Amgen, Takeda and UCB join forces in new COVID-19 drug repurposing study Sponsored: Predicting Landfall: A Dynamic Control Room for Taking on the COVID-19 Landscape Wilson, Penn ink Regeneron pact to use gene therapy tech to deliver COVID-19 antibodies Healthcare roundup: AMA, AHA, ANA back 'science-based' vaccine process Biopharma roundup: Regeneron taps Penn, Jim Wilson for antibody nasal spray; Trump's pandemic adviser Atlas hits the exit Trinity Health posts $112M in Q3 earnings as system rebounds from COVID-19 drop Cleveland Clinic posts increased Q3 income, but profits still down for first 9 months of 2020 AMGA urges CMS to continue to allow for telephonic visits in Medicare Advantage Featured Story | By Eric Sagonowsky Throughout the pandemic, White House officials have twisted arms at the FDA—and sometimes succeeded. Now, in the final months of the Trump administration, agency chief Stephen Hahn, M.D., has been summoned to explain why FDA hasn't authorized Pfizer's vaccine yet, Axios reports. read more |
| |
|---|
|
Top Stories By Robert King Bipartisan lawmakers introduced a COVID-19 relief package that includes $100 billion for providers and short-term liability protections from lawsuits related to the pandemic. read more By Angus Liu Even as the FDA has already approved or authorized several COVID-19 drugs, there's still plenty of room for better therapies for a broad variety of patients. Now, three pharma companies have decided to assess drugs from their own portfolios in a new clinical trial among hospitalized patients. read more Sponsored by: Syneos Health When it comes to COVID-19 commercialization, multiple disrupters are likely to impact an asset’s trajectory. Gain the real-time perspective needed to pivot fast in an ever changing environment. read more By Ben Adams Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID-19 antibody cocktail using AAV tech in the hope of curbing infection via a nasal spray. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner Regeneron tapped Jim Wilson and the University of Pennsylvania to help deliver its antibody cocktail intranasally. Amgen, Takeda and UCB launched an adaptive trial to see whether a trio of drugs could curb inflammatory responses in COVID patients. Trump's pandemic advisor Scott Atlas hit the exit. And Europe will review Pfizer's shot by Dec. 29. read more By Robert King Trinity Health posted a $112 million in operating income for its third quarter as the major system has been able to offset small declines in its patient volume caused by COVID-19. read more By Robert King Cleveland Clinic posted a $49 million profit for the first nine months of 2020, a drop from the $1.2 billion it generated in the same period in 2019. read more By Paige Minemyer A major physician group is urging the Centers for Medicare & Medicaid Services to continue allowing for audio-only patient visits under the COVID-19 pandemic. read more |
